Results from the 2016 Dayton Area Drug Survey (DADS) show declines (or stability) in the lifetime and current prevalence of use of virtually every drug among 12th grade students when compared with results from the 2014 DADS.
Montgomery County Commissioner Dan Foley has established a Collective Impact Collaborative to attack the heroin/opioid epidemic that is plaguing our community. The goals are to reduce the number of people dying from drug overdoses and reduce the number of people addicted.
“Confronting this public health/safety crisis will be incredibly difficult, but we must do it together. We must attack this epidemic that is taking the lives of our family members, friends and neighbors and affecting every community in Montgomery County,” said Commissioner Foley
Professionals and the general public are invited to learn from three national experts in the fields of problem gambling treatment and research. They will discuss how to prevent problem gambling as well as the motivations, trends, treatment and support options available to problem gamblers.
Visit our Trianing and Events Page HERE or view our Calendar HERE
Effective July 1, 2016, the Montgomery Co. ADAMHS will begin transition to a new sliding fee scale. The sliding fee scale for Medicaid billable services will begin at 139% of the Federal Poverty Level.
Montgomery County ADAMHS promotes wellness and recovery that reinforces and sustains healthy individuals, families, and communities that are free from stigma related to mental illness and addictions.
To provide community leadership in planning, developing, and supporting high quality, innovative, and accountable mental health and addiction services and strategies so that all Montgomery County residents achieve wellness.
The ADAMHS for Montgomery County opposes the legalization and commercialization of marijuana for
recreational purposes. In addition, legalizing marijuana for medical use should not be decided by legislative or voter initiative. Marijuana should be
subject to the same research, consideration and study as any other potential medicine, under the standards of the U.S. Food and Drug Administration (FDA).
The supports controlled research into the benefits of cannabis-based medicines which follow the basic tenets of good medicine, and which would provide
scientifically-valid support for the conditions it is proven to help; controlled strength and purity; appropriate dosage levels; and safe means of administration.